Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469742 | 0.79 | NQO2 (0.36) | — | |
| SCHEMBL17469741 | 0.74 | MAPK14 (0.33) | ALDH1A1F7 | |
| SCHEMBL17469846 | 0.74 | PKM (0.38) | ALDH1A1PKM | |
| SCHEMBL17469730 | 0.67 | TMPRSS2 (0.48) | MEN1RAB9AKMT2ACYP1A2ST14 | |
| SCHEMBL17469728 | 0.64 | TMPRSS2 (0.40) | PRSS1MEN1RAB9AKMT2ACYP1A2 | |
| SCHEMBL17469631 | 0.61 | ALDH1A1 (0.46) | RAB9AKMT2AALDH1A1 | |
| SCHEMBL3643020 | 0.61 | ALDH1A1 (0.59) | CYP1A2DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL17469657 | 0.60 | TMPRSS2 (0.56) | PRSS1MEN1RAB9AKMT2AST14 | |
| SCHEMBL21531026 | 0.59 | ALDH1A1 (0.63) | RAB9AKMT2AACKR3ALDH1A1PKM | |
| SCHEMBL30074587 | 0.59 | ALDH1A1 (0.63) | RAB9AKMT2AACKR3ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | PRSS1 3985/4885TMPRSS15 2311/4885MEN1 1462/4885 |
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | PRSS1 3985/4885TMPRSS15 2311/4885MEN1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.